Alexandria Real Estate Equities, Inc. (ARE) saw consistent outperformance against competitors alongside some volatility. Reinhart Partners LLC divested 4,957 shares, while several other entities like Harbor Investment Advisory and SG Americas Securities trimmed their holdings. Despite this, other firms like Sanctuary Advisors and Brown Financial Advisors have newly invested in ARE. The company also reported
2Q24 and
1H24 FFO per share adjusted figures of $2.36 and $4.71 respectively, and witnessed net
income per share stand at $0.25 for 2Q24 and $1.22 for 1H24. Furthermore, strategic endeavors such as the
$150M sale of Seattle Life Science property, closing the disposition of 1165 Eastlake Avenue East, and the establishment of long-term leases with AstraZeneca and a top 20 pharmaceutical company for R&D centers demonstrate their commitment to growth. Despite a few analysts downgrading ARE stock, it surpassed Q2
FFO estimates and is still considered a valuable addition to
dividend portfolios. Moreover, its
sustainable design achievements and founder's recognition as a Life Sciences Icon & Influencer emphasize ARE's innovation and impact in the industry.
Alexandria Real Estate Equities ARE News Analytics from Mon, 23 Oct 2023 07:00:00 GMT to Sat, 12 Oct 2024 10:56:18 GMT -
Rating 4
- Innovation 6
- Information 7
- Rumor 6
